Activity

Under optimal conditions, the immunosensor displayed a wide linear range from 0.0001 to 100 U mL-1 with an ultralow limit of detection of 53.5 μU mL-1 (S/N = 3) for carbohydrate antigen 19-9. Considering these advantages, namely self-producing H2O2 and easy operation, this strategy paves a new way to design other novel sensors.Inorganic phosphate (Pi)-sensing is a key application in many disciplines, and biosensors emerged as powerful analytic tools for use in environmental Pi monitoring, food quality control, basic research, and medical diagnosis. Current sensing techniques exploit either electrochemical or optical detection approaches for Pi quantification. Here, by combining the advantages of a biological Pi-receptor based on the bacterial phosphate binding protein with the principle of thermophoresis, i.e. the diffusional motion of particles in response to a temperature gradient, we developed a continuous, sensitive, and versatile method for detecting and quantifying free Pi in the subnanomolar to micromolar range in sample volumes ≤10 μL. By recording entropy-driven changes in the directed net diffusional flux of the Pi-sensor in a temperature gradient at defined time intervals, we validate the method for analyzing steady-state enzymatic reactions associated with Pi liberation in real-time for adenosine triphosphate (ATP) turnover by myosin, the actomyosin system and for insoluble, high molecular weight enzyme-protein assemblies in biopsy derived myofibrils. Particular features of the method are (1) high Pi-sensitivity and selectivity, (2) uncoupling of the read-out signal from potential chemical and spectroscopic interferences, (3) minimal sample volumes and nanogram protein amounts, (4) possibility to run several experiments in parallel, and (5) straightforward data analysis. The present work establishes thermophoresis as powerful sensing method in microscale format for a wide range of applications, augmenting the current set of detection principles in biosensor technology.A molecularly imprinted sol-gel (MISG)/Au@Ag core-shell NU sensor is proposed for organic vapor detection in an optical fiber-based reflection mode. The compact structure design of the system in the reflection model is promising for practical use as a portable and rapid responsivity sensing probe. Volatile organic acids (OAs) are analogs to biogenetic volatile organic vapors related to specific human diseases. Here, Au@Ag core-shell nano-urchins exhibiting branched tips were synthesized and deposited on indium tin oxide (ITO) glass in small dimer and trimmer clusters to generate an enhanced electric field. A MISG solution was then spin-coated on the substrate to fabricate MISG-LSPR sensors, and three types of MISGs were developed for the detection of hexanoic acid, heptanoic acid and octanoic acid. The normalized spectral response indicated selectivity of the MISG-LSPR sensors for the corresponding template OAs. With Native Bayes and linear discriminant analysis of the sensor responses, where the latter were detected by the proposed system, single- and mixed-OA vapors could be classified into separate clusters. This signified that the proposed MISG-LSPR sensor can be applied toward pattern recognition of single vapors or multiple vapor mixtures.Pulmonary actinomycosis (PA) is an uncommon pulmonary infectious disease that often is misdiagnosed. Metagenomic next-generation sequencing (mNGS) is a highly sensitive and culture-independent new molecular technology for precise infectious disease diagnosis. Here we report a PA case diagnosed by the combination of a radial endobronchial-ultrasonography guide sheath (R-EBUS-GS) and mNGS, along with a brief review of the literature.

Mass gathering (MG) events are associated with public health risks. During the period January 14 to March 4, 2019, Kumbh Mela in Prayagraj, India was attended by an estimated 120 million visitors. An onsite disease surveillance was established to identify and respond to disease outbreaks.

A health coordination committee was established for planning. Disease surveillance was prioritized and risk assessment was done to identify diseases/conditions based on epidemic potential, severity of illness, and reporting requirement under the International Health Regulations (IHR) of 2005. A daily indicator and event-based disease surveillance was planned. The indicator-based surveillance (IBS) manually and electronically recorded data from patient hospital visits and collected MG area water testing data to assess trends. The event-based surveillance (EBS) helped identify outbreak signals based on pre-identified event triggers from the media, private health facilities, and the food safety department. Epidemic intelligrolled.

This onsite disease surveillance imparted a public health legacy by successfully implementing an epidemic intelligence enabled system for early disease detection and response to monitor public health risks. Acute respiratory illnesses emerged as a leading cause of morbidity among visitors. Future MG events should include disease surveillance as part of planning and augment capacity for acute respiratory illness diagnosis and management.

This onsite disease surveillance imparted a public health legacy by successfully implementing an epidemic intelligence enabled system for early disease detection and response to monitor public health risks. Acute respiratory illnesses emerged as a leading cause of morbidity among visitors. Future MG events should include disease surveillance as part of planning and augment capacity for acute respiratory illness diagnosis and management.

Tenofovir alafenamide (TAF) is a preferred nucleotide reverse transcriptase inhibitor used in the treatment of HIV. Co-administration of TAF with rifabutin (RFB) is not recommended due to concerns that RFB decreases TAF gastrointestinal absorption. The objective of this study was to determine the efficacy of antiretroviral therapy regimens that include the co-administration of TAF and RFB.

Persons with HIV (PWH) who received TAF-RFB co-administration for ≥1 month were identified retrospectively. The primary outcome was the maintenance of HIV viral load <200 copies/mL (cpm) for those already on HIV therapy at RFB initiation, or suppression of viral load to <200 cpm for those with unsuppressed HIV viral load prior to TAF-RFB co-administration.

Twenty-two PWH met the inclusion criteria. Camostat Four out of five patients (80%) maintained a viral load <200 cpm and 15/17 (88%) achieved a viral load <200 cpm during TAF-RFB co-administration. After the exclusion of patients who self-discontinued therapy or were lost to follow-up, 19/19 (100%) met the combined primary endpoint of HIV viral load <200 cpm.